| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.100 | Biomarker | group | BEFREE | Interferon-beta (IFN-beta) has demonstrated a potent antitumor effect on many types of cancer cell lines in vivo. | 20138387 | 2010 | ||||
|
0.100 | Biomarker | group | BEFREE | Interferon-beta (IFN-beta) has been found to have anti-tumor properties against a variety of malignancies through different mechanisms. | 19306089 | 2009 | ||||
|
0.100 | Biomarker | group | BEFREE | The oncolytic adenovirus expressing IFN-beta may provide a novel approach for cancer gene therapy. | 18618506 | 2008 | ||||
|
0.100 | AlteredExpression | group | BEFREE | We hypothesized that interferon-beta (IFN-beta) expression from an oncolytic vaccinia strain incapable of responding to this cytokine would have dual benefits as a cancer therapeutic: increased anticancer effects and enhanced virus inactivation in normal tissues. | 18162040 | 2007 | ||||
|
0.100 | Biomarker | group | BEFREE | Interferon-beta gene therapy is expected to become widely available for clinical use in cancer patients, and this new strategy might be extended to molecular targeting therapy, or used in combination with cell therapy or other therapies. | 15546502 | 2004 | ||||
|
0.100 | Biomarker | group | BEFREE | De novo mda-7 mRNA expression is also detected in human melanocytes and expression is inducible in cells of melanocyte/melanoma lineage and in certain normal and cancer cell types following treatment with a combination of IFN-beta plus MEZ. | 11704829 | 2001 | ||||
|
0.100 | GeneticVariation | group | BEFREE | IFN-alpha and IFN-beta genes are located at 9p21-22, the site of frequent homozygotic deletions in cancer. | 10807049 | 2000 | ||||
|
0.100 | Biomarker | group | BEFREE | Our results reveal the following: (a) for those cases in which loss has occurred, the region of common loss lies on the short (p) arm of the chromosome; (b) loss of genetic information from the short arm of chromosome 9 occurs frequently in glial tumors of intermediate (anaplastic, grade III) and high (glioblastoma, grade IV) histological malignancy (10 of 20 cases) but not in tumors of low (grade II) histological malignancy (0 of 10 cases); (c) tumors with 9p deletions are hemi- or nullizygous for interferon beta-1 and the interferon alpha gene cluster; (d) cases of interferon nullizygosity occur exclusively among tumors of highest histological malignancy (glioblastoma). | 1998958 | 1991 |